Turkey: Roche Is Absolved From The Long-Standing Investigation

Last Updated: 22 April 2019
Article by Bora Ikiler and Sercan Sağmanlıgil

Background of the Case

Nine years ago, Corena, a pharmaceutical warehouse, lodged a complaint about Roche on the basis that the distribution agreement of Roche which includes an export ban for the warehouses violates the Article 4 of the Law No: 4054 ("Competition Code"). In addition, it is also alleged that Roche had forced the wholesalers not to provide Roche branded products to Corena.

Therefore, in the preliminary investigation, the Board mainly examined the following allegations:

  • Direct and indirect export ban provisions which are binding for Corena.
  • The allegation that Roche has applied pressure to the wholesalers for preventing their supply to Corena.

Pursuant to its examination, the Board concluded that the export ban does not fall within the scope of the Competition Code as it does not have any effect on the Turkish market. Moreover, the Board determined that there is not any sufficient evidence to initiate an investigation against Roche in line with the second allegation. It also stated that it is not possible to associate the export ban with the existence of wholesaler' refusal to deal with Corena.

Upon Corena's appeal, the Council of State reviewed the case and concluded that the Board has not sufficiently examined the evidence in its preliminary investigation. The Council of State also stated that the indirect export ban should have an impact on the Turkish Market. Pursuant to annulment decision, the Turkish Competition Authority ("TCA") decided to initiate a full-fledged investigation.

Recently, the long-standing process finally came to an end and the Board published its reasoned decision regarding the investigation. The decision creates a significant precedent as it demonstrates the final position of the TCA towards the application of export ban which is a quite hot topic nowadays in the pharmaceutical sector.

Before digging into the decision, it is worth to mention that Roche was not the first undertaking in the sector that the TCA examined its export ban provisions. Therefore, initially, we will briefly summarize the TCA's previous decisions regarding the export ban issues within the pharmaceutical industry. Then, we will clarify the TCA's recent position in the Roche decision.

Parallel export from past to today

Within the last ten years, the Board ruled several important decisions which strive to address the exportation issue in the pharmaceutical industry.

As the pharmaceutical industry is strictly regulated in Turkey and the prices in the industry are determined by the government, Turkish markets ended up having eminently cheap products when compared to foreign markets. This led to an increase in the export of the products.

As exports reduce the motivation of the manufacturers to conduct R&D activities which is a highly costly activity that can only be realized if there is a forecasted gain, TCA takes a positive approach towards export limitations.

As previously mentioned, TCA holds the position that the export ban does not fall into the jurisdictional scope of the Competition Code since it has no effect in the Turkish market. Similar analyses on export limitation can also be found in the Novo Nordisk1 and Takeda2 decisions of the TCA as well.

At this point, it should be noted that although the TCA has a positive approach towards the export limitations, as it can be clearly seen from the Board decisions export ban is not sufficient to provide control over the distribution of the pharmaceutical products and manufacturers has been striving to find an additional solution to combat with the unrestrained export.

In this respect, the Board has also closed the doors for selective distribution system which could be an alternative solution. In the Pfizer3  decision, the Board concluded that the warehouses finance the pharmacies for them to maintain the availability of products in the market, thus limiting the number of warehouses will have a significant impact on the competitive nature of the distribution market.

Finally, the recent Roche decision includes significant evaluations which demonstrate the final position of the TCA regarding export ban or alternative solutions for combating against parallel exportation in the pharmaceutical sector.

What does Roche decision say?

In its reasoned decision, the Board makes significant evaluations regarding export ban applications. It states that the warehouses have no intention to contribute the customer welfare and parallel exportation will only serve the warehouses which are now more than 85. 

Moreover, it is also observed that the preservation of the parallel exportation will increase the competition among the pharmaceutical warehouses and the customers will benefit from the enhanced service quality.

In this respect, we may conclude that unlike the Pfizer decision, the Board handles the issue from a different viewpoint and it does not solely focus on the welfare of the warehouses.

In addition, the Board emphasized that the prevention of parallel exports is not only for the benefit of the pharmaceutical warehouses but also the public health.  Hence, the Board states that banning the export of pharmaceutical products is also compliant with the policies of the Ministry of Health.

It is also highlighted that there is no sufficient evidence which supports the allegation that Roche forced the warehouses to restrict supplies to Corena.

Therefore, it is observed that the Board is gradually changing its position regarding the competition among the warehouses and it starts giving positive signals that it may bring the welfare of the manufacturers in question as well.

In this respect, it remains to be seen whether the change in the attitude of the Board would go that far to leave room for more conventional mechanisms such as selective distribution systems.


1 Novo Nordisk Decision dated 05.02.2015 and numbered 15-06/71-29.

2  Takeda İlaç/Anika Decision dated 03.04.2014 and numbered 14-13/242-107.

3 Pfizer Decision dated 02.08.2007 and numbered 07-63/774-281.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions